MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine

Ítems similars

• Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes
  per: Breccia, Massimo, et al.
  Publicat: (2011)
• Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome
  per: Molica, Matteo, et al.
  Publicat: (2014)
• Low Incidence Rate of Opportunistic and Viral Infections During Imatinib Treatment in Chronic Myeloid Leukemia Patients in Early and Late Chronic Phase.
  per: Breccia, Massimo, et al.
  Publicat: (2011)
• LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
  per: Michelina Santopietro, et al.
  Publicat: (2011-01-01)
• The role of azacitidine in the management of myelodysplastic syndromes (MDS)
  per: Götze, KS, et al.
  Publicat: (2009)